Preferred in vivo probe P450 substrates
Substrate | |||
|---|---|---|---|
|
P450
|
November 1999 FDA Guidance for Industry In Vivo Drug Metabolism/Drug
Interaction Studies... |
Basel Conference (November 2000), sponsored by the FDA, EUFEPS, and AAPS
(Tucker et al., 2001)
| |
| CYP1A2 | Theophylline | Caffeine | |
| CYP2B6 | Bupropion | ||
| CYP2C9 | S-Warfarin | Tolbutamide | |
| CYP2C19 | S-Mephenytoin, omeprazole | ||
| CYP2D6 | Desipramine | Debrisoquine (not available in the United States) dextromethorphan | |
| CYP2E1 | Chlorzoxazone | ||
|
CYP3A
|
Midazolam, buspirone, felodipine, simvastatin, lovastatin
|
Midazolam (i.v. ± p.o.), p.o. midazolam + i.v. erythromycin,
simvastatin, atorvastatin
| |